21. De Clercq E (2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2: 581–587. 22. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, et al. (2004) Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection. JAIDS: Journal of Acquired Immune Deficiency Syndromes 37: 1253–1262. 23. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, et al. (2000) Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers. Antimicrob Agents Chemother 44: 1667–1673. 24. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, et al. (2007) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non- Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and//or cytokine treatment: compassionate use data. Bone Marrow Transplant 41: 331–338. 25. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, et al. (2008) Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112: 990–998. 26. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, et al. (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113: 5720–5726. 27. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, et al. (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107: 3772–3778. 28. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, et al. (2003) Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102: 2728–2730. 29. Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, et al. (2007) AMD3100 and CD26 Modulate Mobilization, Engraftment, and Survival of Hematopoietic Stem and Progenitor Cells Mediated by the SDF-1/CXCL12- CXCR4 Axis. Ann NY Acad Sci 1106: 1–19. 30. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, et al. (2004) Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin’s Lymphoma. J Clin Oncol 22: 1095–1102. 31. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, et al. (2005) Pro- inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen- induced arthritis. Arthritis Research & Therapy 7: R1208–R1220. 32. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, et al. (2001) AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-{gamma} Receptor-Deficient Mice. J Immunol 167: 4686–4692. 33. Slayton WB, Li X-M, Butler J, Guthrie SM, Jorgensen ML, et al. (2007) The Role of the Donor in the Repair of the Marrow Vascular Niche Following Hematopoietic Stem Cell Transplant. Stem Cells 25: 2945–2955. 34. Kiel MJ, Yilmaz O¨H, Iwashita T, Yilmaz OH, Terhorst C, et al. (2005) SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal Endothelial Niches for Stem Cells. Cell 121: 1109–1121. 35. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL (2005) Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 202: 1599–1611. AMD3100 Enhances Engraftment 36. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, et al. (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointes- tinal tract. Nature 393: 591–594. 37. Genzyme (2009) Plerixafor Injection Investigator’s Brochure. Version 13, 27 May 2009. 38. Chen BJ, Cui X, Sempowski GD, Gooding ME, Liu C, et al. (2002) A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. Blood 99: 364–371. 39. Chen B, et al. (2010) Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman Primates. PLOS One, In Press. 40. Uchida N, Tsukamoto A, He D, Friera AM, Scollay R, et al. (1998) High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. The Journal of Clinical Investigation 101: 961–966. 41. Kang Y, Chao NJ (2009) Immune reconstitution. In: Wingard JR, Gastineau D, Leather H, Snyder EC, Szczepiokowski ZM, eds. ‘‘Hematopoietic Stem Cell Transplantation: A Clinician’s Handbook’’ Bethesda, MD, AABB Press. pp 181–196. 42. Beutler B (2005) The Toll-like receptors: analysis by forward genetic methods. Immunogenetics 57: 385–392. 43. Xu J, Mora A, Shim H, Stecenko A, Brigham KL, et al. (2007) Role of the SDF- 1/CXCR4 Axis in the Pathogenesis of Lung Injury and Fibrosis. Am J Respir Cell Mol Biol 37: 291–299. 44. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, et al. (2004) Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. The Journal of Clinical Investigation 114: 438–446. 45. Ferrara JLM, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. The Lancet 373: 1550–1561. 46. Xu J, Torres E, Mora AL, Shim H, Ramirez A, et al. (2008) Attenuation of Obliterative Bronchiolitis by a CXCR4 Antagonist in the Murine Heterotopic Tracheal Transplant Model. The Journal of Heart and Lung Transplantation 27: 1302–1310. 47. Dominici M, Rasini V, Bussolari R, Chen X, Hofmann TJ, et al. (2009) Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. ;Blood:blood-2008-2010-183459. 48. Salter AB, Meadows SK, Muramoto GG, Himburg H, Doan P, et al. (2009) Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitu- tion in vivo. Blood 113: 2104–2107. 49. Abraham M, Beider K, Wald H, Weiss ID, Zipori D, et al. (2009) The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 23: 1378–1388. 50. Plett PA, Stacy MF, Frances MW, Rafat A, Christie MO-T (2002) Treatment of circulating CD34+ cells with SDF-1Iˆ6 or anti-CXCR4 antibody enhances migration and NOD/SCID repopulating potential. Experimental Hematology 30: 1061–1069. 51. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, et al. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 277: 24515–24521. 52. Chen BJ, Cui X, Sempowski GD, Domen J, Chao NJ (2004) Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 103: 4344–4352. 53. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow cytometry. Journal of Immunological Methods 171: 131–137. PLoS ONE | www.plosone.org 14 June 2010 | Volume 5 | Issue 6 | e11316